683 Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

683 Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.5M	Sell	290,000 -65,000	-18%	-$6.79M	1.75%	16
2026 Q1	$37.4M	Sell	355,000 -25,669	-7%	-$2.27M	1.95%	10
2025 Q4	$33.2M	Sell	380,669 -26,831	-7%	-$2.2M	1.45%	14
2025 Q3	$27.1M	Sell	407,500 -37,500	-8%	-$2.13M	1.41%	19
2025 Q2	$24.6M	Sell	445,000 -55,000	-11%	-$2.64M	1.62%	16
2025 Q1	$24.2M	Buy	500,000 +90,000	+22%	+$3.77M	1.67%	16
2024 Q4	$15.8M	Sell	410,000 -10,000	-2%	-$436K	0.98%	23
2024 Q3	$18.9M	Sell	420,000 -184,449	-31%	-$7.45M	1.44%	21
2024 Q2	$20.9M	Sell	604,449 -95,551	-14%	-$2.8M	1.58%	17
2024 Q1	$20.3M	Sell	700,000 -15,000	-2%	-$408K	1.48%	19
2023 Q4	$16.4M	Sell	715,000 -17,784	-2%	-$311K	1.34%	24
2023 Q3	$12.2M	Sell	732,784 -81,216	-10%	-$1.58M	0.95%	33
2023 Q2	$22.5M	Buy	814,000 +23,000	+3%	+$576K	1.61%	18
2023 Q1	$18.2M	Buy	791,000 +583,200	+281%	+$9.79M	1.36%	22
2022 Q4	$2.27M	Buy	+207,800	New	+$1.75M	0.19%	96

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

683 Capital Management's PTGX Position: Q2 2026 in Review

683 Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 18% in Q2 2026, selling an estimated $6.79M and leaving 290,000 shares worth $35.5M. The position accounts for 1.75% of the portfolio, ranked #16.

683 Capital Management first reported a position in PTGX in Q4 2022 and has held it in 15 quarters since. The position peaked at $37.4M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

683 Capital Management held 290,000 shares of Protagonist Therapeutics worth $35.5M as of Q2 2026.
683 Capital Management sold 65,000 Protagonist Therapeutics shares in Q2 2026, an estimated $6.79M.
Protagonist Therapeutics made up 1.75% of 683 Capital Management's portfolio in Q2 2026, its #16 holding.
683 Capital Management first reported a position in Protagonist Therapeutics in Q4 2022 and has held it in 15 quarters since.
683 Capital Management's Protagonist Therapeutics position peaked at $37.4M in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.